石四药集团(02005)发布公告，于2026年2月10日的中国第一至八批全国药品集中采购(国家集采)的接续 采购中，集团共45个品种的产品拟中标，涵盖抗感染、心血管系统、唿吸系统、消化系统、神经系统等 治疗领域，预期对集团的业务带来正面影响。 ...

智通财经APP讯，石四药集团(02005)发布公告，于2026年2月10日的中国第一至八批全国药品集中采购 (国家集采) 的接续采购中，集团共45个品种的产品拟中标，涵盖抗感染、心血管系统、唿吸系统、消化 系统、神经系统等治疗领域，预期对集团的业务带来正面影响。 ...

Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 3.17%, ranking 22nd among 31 primary industries, underperforming the CSI 300 index which fell by 1.25% [6][17] - The valuation of the pharmaceutical and biotechnology industry as of February 6, 2026, is a PE (TTM overall method, excluding negative values) of 29.57x, down from 30.31x in the previous period, indicating a downward trend below the average [6][22] - The top three sub-industries in terms of PE (TTM overall method, excluding negative values) are vaccines (46.30x), hospitals (43.34x), and medical consumables (37.71x), while the median is 32.64x, with pharmaceutical distribution having the lowest valuation at 14.88x [22] Industry Trends - The focus in the global pharmaceutical market is on GLP-1 targets, with Eli Lilly's Tirzepatide establishing a leading position in the metabolic disease field due to its clinical value and commercialization performance [9] - The collaboration model between multinational pharmaceutical companies and Chinese biopharmaceutical firms is evolving towards "platform capabilities + multi-project combinations," highlighting the long-term strategic value of underlying innovative capabilities such as sustained delivery technology and peptide R&D platforms [9] - The investment logic in the industry is shifting from single blockbuster products to platform-based, matrixed approaches, and key supply chain segments [9] Investment Recommendations - Focus on innovative pharmaceutical companies with "core technology platforms + diversified pipelines," as their ability to derive multiple values from platforms and achieve cross-border collaboration milestones will be a key advantage [9] - Pay attention to industry chain segments benefiting from drug long-acting and oral trends, including complex formulation processes, high-end delivery technologies, and related peptide CDMO fields [9] - In the context of strong global R&D and production demand, peptide CXO companies that are active in cross-border collaborations, have balanced customer structures, and possess solid compliance systems will continue to share in the industry's high prosperity dividends [9]

Group 1 - The core viewpoint of the articles indicates that AstraZeneca expects a double-digit percentage growth in adjusted earnings per share by 2026, driven by strong sales in its oncology drug business, which will offset the impact of patent expirations on core diabetes drugs [1] - AstraZeneca's fourth-quarter profits and revenues met expectations, with the company forecasting mid-to-high single-digit revenue growth for the year, similar to the 8% increase in 2025, allowing room for potential upward revisions later in the year [1][2] - The company is accelerating its entry into the weight loss drug market, having recently signed a collaboration agreement with China’s CSPC Pharmaceutical Group worth up to $18.5 billion, which includes access to CSPC's long-acting peptide technology platform for developing next-generation weight loss therapies [1] Group 2 - AstraZeneca's self-developed oral GLP-1 drug, elecoglipron, has entered late-stage clinical trials, becoming a key candidate in its obesity treatment pipeline [1] - The company has confidence in managing pricing impacts and is focused on achieving its long-term revenue target of $80 billion by 2030, with several new drugs in clinical development being critical for maintaining growth momentum [2] - Under CEO Pascal Soriot's leadership, AstraZeneca has established a leading position in oncology and is the second-largest listed company on the London Stock Exchange, with key clinical data for new drugs targeting diseases like lung cancer and COPD expected to be released this year [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 於二零二六年二月十日的中國第一至八批全國藥品集中採購（「國家集採」）的接續採購中，本 集團共45個品種的產品擬中標，涵蓋抗感染、心血管系統、呼吸系統、消化系統、神經系統等 治療領域，預期對本集團的業務帶來正面影響。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二六年二月十日 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 自願公告 國家集採接續採購 擬中選結果 ...

Core Viewpoint - Asia-Pacific Pharmaceutical (002370.SZ) announced the establishment of a wholly-owned subsidiary, Zhejiang Yatai Lizhong Investment Holding Co., Ltd., with a capital investment of 50 million yuan to enhance its industrial development layout [1] Group 1 - The company plans to use its own funds amounting to 50 million yuan for the establishment of the new subsidiary [1] - The name of the subsidiary is provisional and will be finalized upon approval from the relevant registration authority [1]

随着数百万美国人开始使用GLP-1类减重药，减重药厂商开始投入大量资金面向消费者进行直接的 营销。机构Bernstein分析数据显示，目前约有12%的美国人正在服用这类药物。 2026.02. 10 本文字数：878，阅读时长大约2分钟 作者 | 第一财经 钱童心 美国食品和药物管理局（FDA）日前向减重药司美格鲁肽厂商诺和诺德发出警告信，称该公司的口 服减重药电视广告带有误导性。 FDA的这封警告信正值减重药竞争加剧之际。诺和诺德、礼来等减重药厂商借今年的美国超级碗投 放了大量电视广告。 但诺和诺德称，FDA的最新警告不涉及超级碗广告，而是常规播放的关于司美格鲁肽口服减重药电 视广告。 去年年底，司美格鲁肽口服减重药获得美国FDA批准，成为全球首个获批上市的GLP-1类口服减重 药，早于竞争对手礼来。该药物于今年年初正式在美国上市销售，但尚未在中国上市销售。 在FDA的警告信中，监管机构认为，诺和诺德的电视广告误导性地暗示，与其他GLP-1类减重药相 比，司美股鲁肽口服减重药效果更佳。这种宣传违反了美国联邦食品、药品和化妆品法。FDA要求 诺和诺德立即采取行动解决这种违规行为，包括停止所有包含误导性信息的广 ...

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. (哈药股份) announced that its subsidiary, Harbin Pharmaceutical Group Pharmaceutical Factory (哈药总厂), received approval from the National Medical Products Administration for the injectable Cefoperazone Sodium, indicating successful consistency evaluation of quality and efficacy for generic drugs [1]. Group 1 - The approved injectable Cefoperazone Sodium is available in two dosages: 1.0g and 0.5g, with respective notification numbers 2026B00713 and 2026B00715 [1]. - Cefoperazone Sodium is indicated for infections caused by sensitive bacteria, including lower respiratory tract infections, urogenital infections, gynecological infections, bacteremia/sepsis, skin and soft tissue infections, abdominal infections, bone and joint infections, and central nervous system infections [1].

恒生港股通创新药指数是ETF跟踪的指数中首批"纯度"达100%的创新药指数，精准汇聚港股创新药领军 企业；中证港股通医药卫生综合指数从港股通范围内选取医药卫生行业中市值较大的50只上市公司作为 样本，覆盖创新药、医疗器械等领域。投资者可通过港股通创新药ETF易方达（159316）、港股通医药 ETF易方达（513200）等跟踪上述指数的产品，精准捕捉医药产业发展机遇。 1月30日，石药集团与阿斯利康达成总额高达185亿美元的合作，首付款12亿美元，创下中国药企对外授 权交易新纪录。2月8日，信达生物与礼来达成88.5亿美元合作，首付3.5亿美元，创新采用"端到端共 研"模式。据统计，2026年以来创新药BD合作的首付款规模，已超越2025年全年最高单季度水平，总交 易金额已达332.8亿美元，产业出海势头迅猛。 同时，龙头公司业绩预告验证了高景气度。信达生物、荣昌生物与君实生物预告2025年营业收入分别约 为110亿元、32.5亿元和25亿元，同比大幅增长45%、89%和32%，强劲的业绩增长为板块提供了坚实的 基本面支撑。 2月10日，港股医药板块全天强势领涨，截至15:15，恒生港股通创新药指数上涨2.7 ...

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) announced that its wholly-owned subsidiary, Anhui Fuyuan, has received a drug registration certificate from the National Medical Products Administration for the production of Bromhexine Hydrochloride Oral Solution [1] Group 1 - The drug approved is Bromhexine Hydrochloride Oral Solution, with a specification of 200ml:160mg [1] - The certificate number for the drug registration is 2026S00394 [1]